Literature DB >> 33320931

Unveiling the immune infiltrate modulation in cancer and response to immunotherapy by MIXTURE-an enhanced deconvolution method.

Elmer A Fernández1, Yamil D Mahmoud2, Florencia Veigas3, Darío Rocha4, Matías Miranda5, Joaquín Merlo3, Mónica Balzarini6, Hugo D Lujan7, Gabriel A Rabinovich1, María Romina Girotti2.   

Abstract

The accurate quantification of tumor-infiltrating immune cells turns crucial to uncover their role in tumor immune escape, to determine patient prognosis and to predict response to immune checkpoint blockade. Current state-of-the-art methods that quantify immune cells from tumor biopsies using gene expression data apply computational deconvolution methods that present multicollinearity and estimation errors resulting in the overestimation or underestimation of the diversity of infiltrating immune cells and their quantity. To overcome such limitations, we developed MIXTURE, a new ν-support vector regression-based noise constrained recursive feature selection algorithm based on validated immune cell molecular signatures. MIXTURE provides increased robustness to cell type identification and proportion estimation, outperforms the current methods, and is available to the wider scientific community. We applied MIXTURE to transcriptomic data from tumor biopsies and found relevant novel associations between the components of the immune infiltrate and molecular subtypes, tumor driver biomarkers, tumor mutational burden, microsatellite instability, intratumor heterogeneity, cytolytic score, programmed cell death ligand 1 expression, patients' survival and response to anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed cell death protein 1 immunotherapy.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  RNA sequencing; cancer; deconvolution; digital cytometry; immune infiltrate; immunotherapy

Mesh:

Year:  2021        PMID: 33320931      PMCID: PMC8294562          DOI: 10.1093/bib/bbaa317

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   11.622


  57 in total

1.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

2.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

Review 4.  Computational deconvolution of transcriptomics data from mixed cell populations.

Authors:  Francisco Avila Cobos; Jo Vandesompele; Pieter Mestdagh; Katleen De Preter
Journal:  Bioinformatics       Date:  2018-06-01       Impact factor: 6.937

5.  Classification and characterization of microsatellite instability across 18 cancer types.

Authors:  Ronald J Hause; Colin C Pritchard; Jay Shendure; Stephen J Salipante
Journal:  Nat Med       Date:  2016-10-03       Impact factor: 53.440

6.  Tertiary lymphoid structures improve immunotherapy and survival in melanoma.

Authors:  Rita Cabrita; Martin Lauss; Adriana Sanna; Marco Donia; Mathilde Skaarup Larsen; Shamik Mitra; Iva Johansson; Bengt Phung; Katja Harbst; Johan Vallon-Christersson; Alison van Schoiack; Kristina Lövgren; Sarah Warren; Karin Jirström; Håkan Olsson; Kristian Pietras; Christian Ingvar; Karolin Isaksson; Dirk Schadendorf; Henrik Schmidt; Lars Bastholt; Ana Carneiro; Jennifer A Wargo; Inge Marie Svane; Göran Jönsson
Journal:  Nature       Date:  2020-01-15       Impact factor: 49.962

7.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

8.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

9.  RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types.

Authors:  Gianni Monaco; Bernett Lee; Weili Xu; Seri Mustafah; You Yi Hwang; Christophe Carré; Nicolas Burdin; Lucian Visan; Michele Ceccarelli; Michael Poidinger; Alfred Zippelius; João Pedro de Magalhães; Anis Larbi
Journal:  Cell Rep       Date:  2019-02-05       Impact factor: 9.423

10.  Determining cell type abundance and expression from bulk tissues with digital cytometry.

Authors:  Aaron M Newman; Chloé B Steen; Chih Long Liu; Andrew J Gentles; Aadel A Chaudhuri; Florian Scherer; Michael S Khodadoust; Mohammad S Esfahani; Bogdan A Luca; David Steiner; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Biotechnol       Date:  2019-05-06       Impact factor: 54.908

View more
  4 in total

1.  Evaluating the impact of age on immune checkpoint therapy biomarkers.

Authors:  Rossin Erbe; Zheyu Wang; Sharon Wu; Joanne Xiu; Neeha Zaidi; Jennifer La; David Tuck; Nathanael Fillmore; Nicolas A Giraldo; Michael Topper; Stephen Baylin; Marc Lippman; Claudine Isaacs; Reva Basho; Ilya Serebriiskii; Heinz-Josef Lenz; Igor Astsaturov; John Marshall; Josephine Taverna; Jerry Lee; Elizabeth M Jaffee; Evanthia T Roussos Torres; Ashani Weeraratna; Hariharan Easwaran; Elana J Fertig
Journal:  Cell Rep       Date:  2021-08-24       Impact factor: 9.423

2.  Oral squamous cell carcinoma (OSCC) tumors from heavy alcohol consumers are associated with higher levels of TLR9 and a particular immunophenotype: Impact on patient survival.

Authors:  Nicolás Bolesina; Gerardo Gatti; Silvia López de Blanc; Sabrina Dhooge; Darío Rocha; Elmer Fernandez; Ruth Ferreyra; Vanesa Palla; Verónica Grupe; Rosana Morelatto; Mariana Maccioni
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

3.  Identification of circadian clock genes as regulators of immune infiltration in Hepatocellular Carcinoma.

Authors:  Zhen Zhang; Zicheng Liang; Wenhui Gao; Shuxian Yu; Zongwei Hou; Kexin Li; Puhua Zeng
Journal:  J Cancer       Date:  2022-09-01       Impact factor: 4.478

4.  Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.

Authors:  Yi Wang; Gui-Qi Zhu; Di Tian; Chang-Wu Zhou; Na Li; Ying Feng; Meng-Su Zeng
Journal:  BMC Cancer       Date:  2022-03-24       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.